Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
You may also be interested in...
Merck Taking Aggressive Approach To Cardiovascular Development
Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.
Neurocrine Inks $575 Mil. Deal With Abbott To Develop and Sell Gynecologic, Elagolix
Elagolix could be the first oral drug approved for endometriosis that does not have severe side effects.